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1792Heart Association developed per-
formance measures to quantify
the use of evidence-based treat-
ments (1). The goal of these
measures is to promote the wide-
spread and uniform application
of best practices in AMI care
and, in turn, improve survival
and quality of life of patients (2).
Current performance measures
assess whether patients are pre-
scribed certain medications (i.e.,
yes/no) but not the potency of
treatment (i.e., dose). However,
trials comparing low versus high
doses of these medications havedemonstrated that optimal dosing is necessary to achieve
the full clinical beneﬁt of these therapies (3–7). Thus, it is
possible that a large number of treated patients are receiving
relatively ineffective therapy but yet still fulﬁll the require-
ments of current performance measures.
Initiating lower doses of secondary prevention medica-
tions at hospital discharge might be reasonable, particularly
in patients with marginal hemodynamic status (e.g., low
blood pressure or heart rate) or left ventricular (LV) systolic
dysfunction. It is desirable, however, for these therapies to be
up-titrated shortly after discharge to the levels with estab-
lished beneﬁt in clinical trials, but the degree to which
providers are intensifying treatment during outpatient
follow-up also is not currently known. If patients are being
sub-optimally dosed with secondary prevention medications
at hospital discharge and if medication up-titration occurs
infrequently during subsequent follow-up, this might explain
why the ﬁndings from clinical trials (where there was clear
evidence of beneﬁt for each medicine promoted by perfor-
mance measures) have been discordant from those in clinical
practice (where the impact of performance measures on
reducing mortality has been underwhelming [8–10]).
Accordingly, we examined the prescribing patterns of
medications quantiﬁed by the performance measures (beta-
blockers, statins, and angiotensin-converting enzyme
inhibitor [ACEI] or angiotensin II receptor blocker [ARB])
in a large multi-center cohort of patients hospitalized
with AMI. We explored prescribing patterns at the time
of hospital discharge and 12 months after discharge as
well as outpatient intensiﬁcation of therapy among those
initially discharged on medication dose regimens that were
below goal.Methods
Study population and protocol. Patients were enrolled in
either of 2 multicenter, prospective cohort studies of
unselected patients hospitalized with AMI in the United
States. Between January 2003 and June 2004, 2,498
patients with AMI were recruited from 19 U.S. hospitalsinto the PREMIER (Prospective Registry Evaluating
Myocardial Infarction: Events and Recovery) (11). Simi-
larly, between June 2005 and December 2008, 4,340
patients with AMI from 24 U.S. hospitals were enrolled
into the TRIUMPH (Translational Research Investigating
Underlying disparities in acute Myocardial infarction
Patients’ Health status) study (12 hospitals participated in
both registries) (12). Both registries employed identical
inclusion and exclusion criteria and were coordinated by the
Mid America Heart Institute. Patients were required to
have biomarker evidence of myocardial necrosis and addi-
tional clinical evidence supporting the diagnosis of an
AMI, including prolonged ischemic signs/symptoms (20
min) or electrocardiographic ST-segment changes during
the initial 24 h of admission. Baseline data, including
discharge medications and doses, were obtained through
chart abstraction and a structured interview by trained
research staff within 24 to 72 h after admission. To be
eligible for the current study, patients had to survive to
hospital discharge and not be discharged against medical
advice or to hospice (90 patients excluded). Thus, our study
sample included 6,748 patients from 31 hospitals, 12 of
which participated in both the PREMIER and TRIUMPH
studies (Fig. 1).
Detailed follow-up interviews were attempted on all
survivors at 1, 6, and 12 months after AMI. In addition to
a report of interval events and an assessment of health status,
participants were asked to read the names and doses of their
medications from their prescription bottles and to report the
number of outpatient visits to cardiologists, cardiac
surgeons, and primary care providers (for care related to their
“heart condition”). For follow-up analyses of this study, we
excluded 503 patients who participated in the interview but
reported taking zero medications of any type (cardiac or
otherwise), because we believed that the therapeutic deci-
sions in these cases were not likely under the control of
a physician.
For each of the 3 medication classes, we excluded
patients with chart-documented contraindications (e.g.,
heart rate <50 beats/min or systolic blood pressure
[SBP] <100 mm Hg for beta-blockers, SBP <100 mm Hg
or a glomerular ﬁltration rate <30 ml/min/1.73 m2 for
ACE/ARBs, patient sensitivities/allergies for each medica-
tion class), which were prospectively abstracted from
the medical records of patients. Furthermore, for analyses
of ACEI/ARBs, we included only patients with LV systolic
dysfunction at the time of AMI (ejection fraction <40%)
(Fig. 1). Each participating hospital obtained Institutional
Research Board approval, and all patients provided written
informed consent for baseline and follow-up assessments.
Medication dose assessment. Our primary outcome was
whether a patient reported taking a goal dose of beta-
blocker, statin, and ACEI/ARB at 12 months after AMI.
To standardize comparisons of medications within the same
class (e.g., metoprolol and carvedilol for beta-blockers), we
classiﬁed medication doses into categories, relative to the
Figure 1 Flowchart of Patients
“Other/unknown meds” refers to patients who reported taking zero medications, patients who were taking medications not U.S. Food and Drug Administration–approved for
patients after myocardial infarction or with concurrent heart failure, or patients with doses that were unknown. ACE ¼ angiotensin-converting enzyme (inhibitor); AMA ¼ against
medical advice; ARB ¼ angiotensin II receptor blocker; CI ¼ contraindications; GFR ¼ glomerular ﬁltration rate; HR ¼ heart rate; LV ¼ left ventricular; SBP ¼ systolic blood
pressure.
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1793target dose for that medication. The target dose for each
medication was deﬁned by the landmark clinical trials that
established clinical beneﬁt for each medication in AMI (see
Online Tables 1 to 3 for target doses for each medication,
the clinical trials demonstrating clinical efﬁcacy, and the
mean achieved doses in the trials). Beta-blockers, statins,
and ACEI/ARBs that were not indicated by U.S. Food and
Drug Administration labeling for patients after AMI or with
concurrent heart failure (and thus did not have a target dose
for these conditions) were considered “other” and excluded
from the respective analyses. For example, medications
such as labetalol and losartan are only indicated for the
treatment of hypertension and thus do not have established
target doses for secondary prevention in AMI. Overall,
this exclusion affected 1% of patients taking beta-blockers,
0% of patients taking statins, and 6% of patients taking
ACEI/ARBs.
A person was considered to be taking a goal dose of
a medication if the dose was at least 75% of the target dose.
A dose that was 50% to 74% of target was considered
moderate intensity, whereas doses below 50% of target were
considered low. Although we excluded patients with
SBP <100 mm Hg from the beta-blocker and ACEI/ARB
analyses, because these patients would be difﬁcult to get
on any dose regime of these medications, patients with
SBP <110 mm Hg might similarly be difﬁcult to up-titrate. As such, a ﬁfth category of patients was created for
the beta-blocker and ACEI/ARB analyses that included
these patients, which was labeled “on medication/unable to
titrate.” The percentages of patients at the various dose
categories (goal, moderate, low, none, on medication/unable
to titrate) of beta-blockers, statins, and ACEI/ARBs were
examined at the time of hospital discharge and at 12-month
follow-up.
Medication up-titration. We also examined rates of up-
titration during the ﬁrst year of follow-up, which was
deﬁned as an increase in the dose category of a medication
from discharge to follow-up (e.g., increasing from a low
dose to a moderate or goal dose). Although 12-month
follow-up was examined, some patients (20% of cohort)
only had 6-month follow-up data, in which case the medi-
cations reported at 6 months were used for the follow-up
analyses. Because up-titration of medications requires
active decision making on the part of a physician, we
examined outpatient follow-up intensity (deﬁned as the
patient-reported monthly rate of outpatient visits to cardi-
ologists, cardiac surgeons, or primary care providers) for
cardiologists and for all physicians (cardiologists and primary
care physicians) to determine its association with achieving
a goal dose of each medication at follow-up.
Statistical analysis. Baseline characteristics of patients
treated with beta-blockers, statins, and ACEI/ARBs were
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1794summarized with proportions for categorical variables,
mean  SD for non-skewed continuous variables, and
medians with interquartile ranges for skewed continuous
variables. The percentage of patients at the various dose
categories (goal, moderate, low, none) of beta-blockers,
statins, and ACEI/ARBs were summarized at the time of
hospital discharge and at 12-month follow-up, and the
percentage of patients at goal at each time point was
compared with the McNemar’s test. The mean outpatient
follow-up rate was compared between those who did versus
those who did not achieve goal dose of each medication at
follow-up Student t tests.
For each of the 3 medication classes, we constructed
multivariable logistic regression models to identify factors
associated with achieving goal dose at follow-up. Patients on
medications/unable to titrate were excluded from these
analyses. We used hierarchical random effects models to
adjust for patient clustering by site. Variables included in
the model were selected a priori on the basis of clinical
judgment of factors that might impact medication titration.
All 3 models included the following variables: discharge
dose, age, sex, race, hypertension, diabetes mellitus, chronic
lung disease, depression (as assessed with the 9-item Patient
Health Questionnaire [13]), type of AMI (ST- or non–ST-
segment elevation), Global Registry of Acute Coronary
Events score (14), and the intensity of outpatient follow-up
(monthly rate of physician visits). In addition to these
variables, the beta-blocker model included SBP, heart rate,
and LV systolic dysfunction at hospital discharge, whereas
the ACEI/ARB model included SBP and estimated
glomerular ﬁltration rate at hospital discharge.
We conducted a number of sensitivity analyses. First, we
evaluated the distribution of discharge SBPs to determine
whether most patients who were discharged on low-dose
regimens of beta-blockers and ACEI/ARBs had lower
blood pressures. Second, because it is recommended that
beta-blockers be more slowly up-titrated in patients with LV
systolic dysfunction, we repeated the analyses, restricting the
model for only patients with normal or mild LV dysfunction
(ejection fraction 40%). Third, for the statin model, even
though data supports treating all patients after AMI with
high statin doses (6,15), we added low-density lipoprotein
cholesterol (LDL-C) levels to the multivariable model to
assess whether in-hospital LDL-C levels were associated
with physician dosing of statins at follow-up. Fourth, we
additionally adjusted for follow-up intensity to cardiologists
speciﬁcally, to evaluate whether type of provider visited was
associated with a greater likelihood of goal dosing at follow-
up. For each of these sensitivity analyses and for the main
models, cubic splines were considered to account for non-
normality of data on age, heart rate, SBP, and LDL.
Missing data analysis. Among patients who survived
12 months, 4% of study participants were contacted but
refused to participate in the interview, and 11% were lost to
follow-up (Fig. 1). To account for potential bias attributable
to those with missing follow-up data, we calculated a non-parsimonious propensity score with successful follow-up as
the dependent variable. An inversely weighted propensity
score was assigned to each responder (16) to provide greater
weight to the data of patients who were most like those
without follow-up. Results were comparable with and
without weighting, so only the unweighted analyses are
presented.
All analyses were conducted with SAS (version 9.2,
SAS Institute, Inc., Cary, North Carolina), and evaluated at
a 2-sided signiﬁcance level of <0.05.Results
Patient population. Of the 6,838 patients enrolled in the
PREMIER and TRIUMPH studies, 41 did not survive to
hospital discharge, and 49 were discharged to hospice or left
the hospital against medical advice. Of the remaining
6,748 patients, 1,413 (20.9%) had left ventricular systolic
dysfunction that was at least moderate in severity and were
thus eligible for the ACEI/ARB analyses (Fig. 1). Baseline
characteristics of the patients in the study cohort who were
eligible for beta-blocker, statin, and ACEI/ARB therapy are
shown in Table 1. The mean age of patients was approxi-
mately 60 years, and two-thirds were male and of white
race. The mean SBP was >120 mm Hg in each group, and
most patients underwent either percutaneous or surgical
coronary revascularization.
Discharge medications. At hospital discharge, most
eligible patients were discharged on some dose of the
3 secondary prevention medications: beta-blockers, 93%;
statins, 88%, and ACEI/ARB, 88% (Fig. 2). However, 40%
of patients were discharged on low doses of beta-blockers,
despite SBPs 110 mm Hg, and only 19% of patients
considered eligible for titration were discharged on goal
doses. Patients without LV systolic dysfunction were dis-
charged on goal doses of beta-blockers at similar rates as
those with LV dysfunction (14.6% vs. 16.3%, p ¼ 0.18).
One-third of patients were discharged on goal doses of
statins, and 19% were on low doses. Among patients with
LV dysfunction, 21% of patients were discharged on a low
or moderate dose of ACEI/ARB but were considered unable
to titrate due to marginal blood pressures. Among the
remainder, 17% were discharged on low doses despite
reasonable SBP and 40% were discharged on goal doses of
ACEI/ARBs.
The distribution of SBPs for patients within each
discharge dose category for beta-blockers and ACEI/ARBs
is shown in Figure 3. Although patients with higher SBPs
were more likely to be discharged on higher doses of these
medications, 46% of patients on low doses and 59% of
patients on moderate doses of beta-blockers had SBPs of at
least 120 mm Hg just before hospital discharge to allow for
a potentially higher dose. Similarly, for those eligible for
ACEI/ARB therapy, 34% of patients on low doses and 45%
on moderate doses had a SBP of at least 120 mm Hg just
before hospital discharge.
Table 1 Baseline Characteristics
Beta-Blocker
(n ¼ 5,368)
Statin
(n ¼ 6,560)
ACE/ARB
(n ¼ 901)
Sociodemographic data
Age (yrs) 59.9  12.6 59.6  12.6 60.5  12.7
Female 32.5% 32.8% 28.2%
White race 69.2% 70.1% 63.6%
High school education 79.0% 79.1% 75.7%
Lives alone 23.5% 23.5% 27.1%
Comorbidities
Hypertension 67.5% 65.3% 67.6%
Depression 19.2% 19.9% 21.7%
Diabetes mellitus 31.2% 29.9% 33.9%
Prior MI 20.4% 21.1% 29.3%
Prior stroke/transient ischemic attack 7.5% 7.4% 8.5%
Prior heart failure 8.9% 9.3% 19.8%
Current smoking 35.7% 37.4% 36.2%
Body mass index (kg/m2) 29.7  6.5 29.4  6.4 28.9  6.1
Estimated GFR* (ml/min/1.73 m2) 77  29 78  29 76  27
LDL-cholesterol (mg/dl) 101 (77–129) 101 (77–129) 97 (71–126)
Clinical presentation
SBP* (mm Hg) 124  17 120  19 120  16
Heart rate* (beats/min) 73  12 73  12 76  13
Peak troponin (ng/dl) 5.6 (1.3–26.1) 6.1 (1.4–28.3) 7.2 (1.7–38.7)
LVEF (%) 50 (40–57) 50 (40–55) 30 (25–35)
LV systolic dysfunction (mod/severe) 19.4% 21.1% 100%
ST-segment elevation MI 42.2% 43.5% 45.3%
GRACE discharge risk score 103  31 102  31 111  32
Treatment characteristics
Cardiac catheterization 90.6% 90.7% 90.1%
Percutaneous coronary intervention 62.6% 63.1% 55.6%
Bypass graft surgery 10.4% 10.0% 10.2%
Length of stay (days) 4 (3–6) 4 (3–6) 5 (3–8)
Values are mean  SD, %, or median (interquartile range). *Assessed at hospital discharge.
ACE/ARB ¼ angiotensin converting enzyme inhibitor/angiotensin II receptor blocker; GFR ¼ glomerular ﬁltration rate; GRACE ¼ Global Registry
of Acute Coronary Events; LDL ¼ low-density lipoprotein; LV ¼ left ventricle; LVEF ¼ left ventricular ejection fraction; mod ¼ moderate;
SBP ¼ systolic blood pressure.
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1795Up-titration during outpatient follow-up. Twelve months
after AMI, only 60% to 70% of patients reported taking any
dose of beta-blockers, statins, or ACEI/ARBs, compared
with approximately 90% at hospital discharge (Fig. 2). Goal
doses of medications were achieved less frequently at
12 months than at discharge, with only 12% (p < 0.001 for
change from discharge to 12 months), 26% (p < 0.001), and
32% (p ¼ 0.74) of eligible patients on goal doses of beta-
blockers, statins, and ACEI/ARBs, respectively. Patients
with LV systolic dysfunction were more likely to be on
goal doses of beta-blockers at 12 months than those without
LV systolic dysfunction (16.2% vs. 9.2%, p < 0.001). Up-
titration of medication dose during outpatient follow-up
occurred infrequently, with dose increases in only 20.4% of
patients on a regimen of beta-blockers, 24.4% of patients on
a regimen of statins, and 31.9% of patients on a regimen of
ACEI/ARB (Online Table 4).
For each of the 3 medications, the frequency of physician
follow-up for patients who were and were not at goal doses is
shown in Figure 4 (frequency of follow-up to a cardiologistor cardiac surgeon is shown in Online Fig. 1). There was
a modestly higher follow-up frequency in patients who
achieved a goal beta-blocker dose at follow-up compared
with those who did not (mean frequency: every 7.5 weeks vs.
every 8.2 weeks, respectively; p ¼ 0.014). For statins and
ACEI/ARBs, there were no signiﬁcant differences in the
mean frequency of physician visits during follow-up among
patients who did and who did not achieve goal doses of
treatment (statins: 8.2 weeks vs. 8.0 weeks, p ¼ 0.76; ACEI/
ARBs: 6.6 weeks vs. 7.1 weeks, p ¼ 0.35). Patients who
achieved goal doses at follow-up had more frequent visits
to cardiologists than those who did not (beta-blockers:
14.0 weeks vs. 16.0 weeks, p < 0.001; statins: 14.4 weeks vs.
16.0 weeks, p ¼ 0.022; ACEI/ARBs: 12.4 weeks vs.
14.0 weeks, p ¼ 0.13).
In site-level hierarchical logistic regression models
adjusting for sociodemographic and clinical factors, in-
cluding intensity of outpatient follow-up, a patient who was
discharged on a goal dose of medication was 6 to 8 times
more likely to be on a goal dose at the 12-month follow-up
Arnold et al. JACC Vol. 62, No. 19, 2013
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1796as compared with those not discharged on goal medication
doses: beta-blockers (adjusted odds ratio [OR]: 6.08 [95%
CI: 3.70 to 10.01]), statins (adjusted OR: 8.22 [95% CI:
6.20 to 10.90]), and ACEI/ARBs (adjusted OR: 5.80
[95% CI: 2.56 to 13.16]); all p < 0.001 (Table 2). Results
were similar when adjusted for cardiac-speciﬁc follow-up
intensity: beta-blockers (adjusted OR: 6.06 [95% CI: 3.68 to
9.97]), statins (adjusted OR: 8.21 [95% CI: 6.20 to 10.90]),
and ACEI/ARBs (adjusted OR: 5.42 [95% CI: 2.40 to
12.23]); all p <0.001.
In these models, patients with hypertension and diabetes
were more likely to be on goal doses of beta-blockers at
follow-up. In addition, patients with LV systolic dysfunc-
tion at the time of AMI were nearly 2 times more likely to
be on goal doses of beta-blockers at follow-up than those
without LV dysfunction (OR: 1.88 [95% CI: 1.40 to 2.53],
p < 0.001). No other patient factors, other than discharge
dose, were signiﬁcantly associated with being on a goal dose
of any of the 3 medications at follow-up. Notably, follow-
up intensity was not signiﬁcantly associated with being
on goal dose for any medication at follow-up. However,
when follow-up was restricted to cardiologists, follow-up
intensity was signiﬁcantly associated with achieving goal
dose at follow-up for cardiology follow-up rate [per 1 visit/
month]; beta-blockers: adjusted OR: 1.69 [95% CI: 1.05 to
2.72], p ¼ 0.031; statins: adjusted OR: 1.37 [95% CI: 1.03
to 1.83], p ¼ 0.033; ACEI/ARBs: adjusted OR: 2.48 [95%
CI: 0.99 to 6.22], p ¼ 0.053). In sensitivity analyses, the
strong association between goal dose of medication at
discharge and follow-up was not materially altered, in-
cluding additional adjustment for in-hospital LDL-CFigure 2 Frequency of Dose Categories After Acute Myocardial Infar
Frequency of dose categories for beta-blockers, statins, and angiotensin-converting enzym
infarction. (A) Dose categories at hospital discharge. (B) Dose categories at follow-up.levels (statin analysis) or limiting the study sample to only
those patients without LV systolic dysfunction (Online
Table 5).
Discussion
In a large prospective cohort of patients hospitalized with
AMI, we found that the use of evidence-based medications
at hospital discharge was high, with approximately 90% of
all eligible patients treated with beta-blockers, statins, and
ACEI/ARBs. However, the prescribed doses for these
medications were below those examined in clinical trials,
with nearly 85% of patients discharged on beta-blocker
doses and two-thirds of patients discharged on statin and
ACEI/ARB doses that were substantially below (<75%)
the doses with established efﬁcacy. This is particularly
concerning in the case of statins, where there should be
few clinical reasons not to start a patient on a goal statin
dose early in the AMI hospital stay. Although discharging
patients on sub-optimal doses of beta-blockers and
ACEI/ARBs might be appropriate clinical care if these
doses are then actively increased to goal doses during
outpatient follow-up, up-titration was uncommon during
the 12 months after AMIdoccurring in only 25% of
patientsdand was not inﬂuenced by blood pressure or
heart rate during hospital stay. In fact, the strongest
predictor of being on a goal dose for any of the 3 medica-
tions during follow-up was being on a goal medication dose
at hospital discharge. Collectively, our ﬁndings suggest most
patients with AMI might be undertreated, despite meeting
criteria for performance measures for secondary preventionction
e (inhibitors) (ACE)/angiotensin II receptor blockers (ARBs) after acute myocardial
Figure 3 SBP at Discharge by Dose Category
Abbreviations as in Figure 1.
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current performance measures that credit providers for using
any dose of medication, even if well below doses with
established clinical beneﬁt.
Prior studies. Actively titrating secondary prevention
therapy to goal doses is particularly important, because the
efﬁcacy of these medications has been demonstrated to be
dose-related. For statins, 2 large clinical trials have shown
that higher statin doses are superior in reducing the risk of
repeat hospital stay and death after an AMI (6,7,17). A trial
comparing low versus high doses of lisinopril and a second
comparative effectiveness study of different doses of losartan
and candesartan both demonstrated that higher doses of
these classes of medications reduced the risk of heart failure,
hospital stays, and death (4,5). Finally, for beta-blockers,
2 trials of heart failure patients showed that target doses of
bucindolol and carvedilol were associated with more
improvement in ejection fraction (3,18), fewer hospital stays
(3), and lower mortality compared with low or moderate
doses (3). Although there has been some conﬂicting
evidence published from an observational registry in which
patients treated with low doses of beta-blockers had lower
mortality than those discharged on high doses (19), most
studiesdand, in particular, clinical trials that do not
have inherent treatment bias found in registriesdhavedemonstrated that the higher treatment doses are most
effective in reducing morbidity and mortality after an AMI.
Although several studies have reported rates of medication
treatment among patients hospitalized with AMI at
discharge and follow-up (20–23), these studies have not
examined treatment doses or intensiﬁcation of therapy over
time. Therefore, they did not establish whether patients
were being treated at doses with established efﬁcacy from
clinical trials. Studies that have examined medication dosing
are limited; however, these have demonstrated patterns of
medication dosing similar to what we found. A study of
606 patients admitted with AMI from 4 hospitals in
1995 found that, although 58% of patients without contra-
indications were discharged on some dose of beta-blocker,
76% were discharged on doses 25% of the target doses
from clinical trials, and only 11% were discharged on doses
of >50% of the target doses (24). Although these authors
did not have information on follow-up, our study highlights
that, despite 15 years of quality improvement, little has
changed with regard to optimal dosing of secondary
prevention medications. A second study of 382 patients with
AMI from 41 hospitals found that 76% of patients dis-
charged on a statin were on the same dose 1 year later, with
intensiﬁcation of therapy occurring in only 12% (25). Our
data both support and extend the ﬁndings of prior studies by
Figure 4 Outpatient Follow-Up Intensity
Frequency of follow-up for patients who did and who did not achieve goal dose at follow-up. ACE ¼ angiotensin-converting enzyme (inhibitor); ARB ¼ angiotensin II receptor
blocker; M ¼ months.
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1798examining patterns of medication prescription and dosing at
both hospital discharge and outpatient follow-up, evaluating
3 proven therapies in AMI, and including data from over 30
centers for greater generalizability.
Potential explanations. There are several potential reasons
as to why patients might have been treated at doses far lower
than those with established efﬁcacy. First, some patients
who are on lower doses of medications are truly receiving
their maximally tolerated dose (e.g., low blood pressure for
beta-blockers and ACEI/ARBs). Furthermore, there mightbe some patients who were not up-titrated due to side
effects, such as light-headedness or myalgias, or due to
patient preference. However, given our sensitivity analyses, it
is unlikely that low blood pressure or other dose-limiting
side effects were the primary limiting factors in achieving
goal doses in most patients.
Second, as hospital stays for AMI have continued to
decrease over the past decade (26), clinicians today have less
time to optimize medical therapy during the index hospital
stay and thus defer intensiﬁcation of medication therapy
Table 2 Patient and Treatment Factors Associated With Being at Goal Medication Dose at 12-Month Follow-Up
Beta-Blocker Statin ACE/ARB
OR (95% CI) p Value OR (95% CI) p Value OR (95% CI) p Value
Medication dose at discharge
Low dose 0.50 (0.30–0.83) 0.008 0.67 (0.47–0.95) 0.024 0.86 (0.34–2.15) 0.748
Moderate dose 0.93 (0.55–1.59) 0.799 1.36 (1.01–1.82) 0.043 1.83 (0.78–4.27) 0.162
Goal dose 6.08 (3.70–10.01) <0.001 8.22 (6.20–10.90) <0.001 5.80 (2.56–13.16) <0.001
Age (/1 yr) 0.98 (0.97–1.00) 0.047 1.00 (0.98–1.02) 0.880 1.00 (0.97–1.03) 0.934
Female 0.94 (0.72–1.23) 0.638 1.01 (0.86–1.19) 0.872 0.75 (0.43–1.29) 0.296
White race 1.25 (0.93–1.68) 0.145 1.02 (0.85–1.24) 0.809 1.04 (0.61–1.79) 0.880
Hypertension 1.46 (1.07–2.00) 0.017 1.02 (0.87–1.20) 0.830 1.33 (0.75–2.34) 0.327
Depression 0.98 (0.71–1.36) 0.910 1.02 (0.84–1.24) 0.807 0.67 (0.35–1.30) 0.235
Diabetes mellitus 1.40 (1.08–1.82) 0.011 0.86 (0.72–1.02) 0.083 0.97 (0.59–1.61) 0.906
Chronic lung disease 1.26 (0.83–1.90) 0.277 0.89 (0.66–1.19) 0.433 1.33 (0.64–2.76) 0.443
ST-segment elevation MI 1.04 (0.80–1.36) 0.752 1.06 (0.91–1.24) 0.429 0.83 (0.50–1.38) 0.465
GRACE score (/1 point) 1.00 (1.00–1.01) 0.365 1.00 (1.00–1.01) 0.407 1.00 (0.98–1.01) 0.724
Follow-up rate (/1 visit/month) 1.09 (0.82–1.45) 0.560 1.01 (0.85–1.21) 0.875 1.33 (0.87–2.03) 0.184
LV dysfunction 1.88 (1.40–2.53) <0.001 NA NA
SBP* (/1 mm Hg) 1.00 (0.99–1.01) 0.727 NA 1.01 (1.00–1.03) 0.092
Heart rate* (/1 beats/min) 1.00 (0.99–1.01) 0.426 NA NA
GFR* (/1 ml/min/1.73 m2) NA NA 1.00 (0.99–1.01) 0.627
*Assessed at hospital discharge.
CI ¼ conﬁdence interval; OR ¼ odds ratio; other abbreviations as in Table 1.
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1799until outpatient follow-up. However, we found that medi-
cation up-titration occurred infrequently, suggesting there is
signiﬁcant clinical inertia in intensifying treatment during
the outpatient period. Interestingly, we found that outpa-
tient follow-up intensity was not associated with an
increased likelihood of achieving goal dose at follow-up.
However, when we restricted follow-up to cardiologists,
there was a modest association between follow-up intensity
and goal dose at follow-up, indicating that specialists might
be more aggressive in up-titrating these medications. The
general lack of active up-titration in the outpatient setting
might be because some clinicians do not view up-titration of
these medications as an important therapeutic goal, are
unaware of the target medication doses (i.e., the doses with
proven clinical efﬁcacy), or have other competing medical
issues that they need to address during follow-up visits (27).
Because current performance measures evaluate only
whether patients are on a medication, clinicians also might
mistakenly equate being on a treatment as being on effective
treatment. This inertia has been shown to be pervasive in the
outpatient management of other chronic medical conditions
such as hypertension (28) and diabetes (29). Thus, strategies
such as improved care coordination at discharge (30) or
outpatient tools that assist providers with automating
medication titrations (e.g., pharmacist-assisted monitoring,
clinical reminders, education, and feedback [31]) might lead
to greater success in treatment intensiﬁcation during follow-
up. Because the protective effects of these medications have
been shown to be dose-related (4–7), the inability to achieve
goal doses at discharge or to intensify treatment during
follow-up represents an important gap in the current quality
of AMI care.Implications. The ﬁndings of our study have important
implications for performance measurement in AMI. The
current measures do not distinguish between those hospitals
that make robust or meager efforts to optimize medical
therapy dosing in patients with AMI. Rates of medication
use at clinically proven doses might be improved if perfor-
mance measures incorporated assessments of medication
dosing. Inclusion of optimal drug dosing at discharge has the
potential to improve outcomes, although this would
understandably be more challenging in terms of data
collection. There is also a need to further our understand-
ing of outpatient care, because the current practice of
evaluating AMI care only at hospital discharge has sub-
stantial limitations in comprehensively capturing the quality
of care of AMI patients. Outpatient registries, such as the
PINNACLE (Practice Innovation And Clinical Excellence)
program (32), might provide additional insights into how
best to track and optimize outpatient cardiac care.
Study limitations. First, our analyses on medication up-
titration during follow-up used information from vital
signs, creatinine, and adverse side effects at hospital
discharge. As a result, some patients might have been mis-
classiﬁed as not being at their maximally tolerated dose of
medication at follow-up (either due to new or worsening
medical factors [e.g., new heart failure or renal dysfunction],
side effects [e.g., light-headedness, myalgias], or patient
preferences). However, because we excluded patients with
SBP <110 mm Hg from these up-titration analyses, we
suspect this is relevant to a minority of patients and does not
diminish our ﬁnding that most patients are not on goal doses
of these important medications 12 months after discharge.
More in-depth qualitative research, with detailed interviews
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1800of patients and physicians, would be particularly useful in
deepening our understanding of why up-titration did not
occur more frequently in many patients.
Second, medications without a speciﬁc indication for
treatment of post-AMI or heart failure patients were
excluded in the study (e.g., nebivolol, olmesartan) but might
be appropriate for particular patients. However, these
excluded patients only represented 1% of patients taking
beta-blockers and 6% taking ACEI/ARBs and therefore
were unlikely to have affected our ﬁndings. Third, we did
not have follow-up data on approximately 15% of surviving
patients; however, we performed a sensitivity analysis in
which we weighted the responses of participants by the
inverse of their likelihood to follow-up, to provide greater
weight to the data of patients who were most like those
without follow-up. Because results were comparable with
and without weighting, it is unlikely that our results were
signiﬁcantly biased by loss-to-follow-up. Finally, although
we identiﬁed gaps in achieving optimal dosing of secondary
prevention medications in post-MI patients, we did not
evaluate the effectiveness of optimal dosing of these medi-
cations because of the likelihood of signiﬁcant bias by
indication with such analyses, whereby patients at higher risk
of adverse outcomes [e.g., LV dysfunction] are more likely to
receive goal doses of medication or undergo more frequent
medication up-titration than lower-risk patients.
Conclusions
We found that most patients hospitalized with an AMI were
routinely discharged on secondary prevention medications at
doses substantially below the levels proven to be efﬁcacious in
clinical trials. These doses were infrequently increased as
outpatients, even after 1 year. Because being on a target
medication dose at discharge was the strongest predictor of
being on a target dose at follow-up, our ﬁndings suggest that
clinicians should attempt to maximize the doses of secondary
prevention therapy during the index hospital stay and to up-
titrate these medications during outpatient follow-up. More
in-depth qualitative research is necessary to deepen our
understanding of why up-titration did not occur more fre-
quently and could provide important insights as to mecha-
nisms by which care can be improved. Performance measures,
in turn, might need to incorporate doses of medications to
better achieve their goal of truly optimal medical therapy.
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